[Balancing efficacy and cost in multiple myeloma immunotherapy: rethinking treatment strategies from a sustainability perspective]
{{output}}
The prognosis of multiple myeloma (MM) has improved dramatically over the past two decades with the introduction of proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and, more recently, immune-based therapies such as chimeric anti... ...
